Adverum Biotechnologies Inc. | Mutual Funds
Mutual Funds that own Adverum Biotechnologies Inc.
JPMorgan Small Cap Growth Fund
1,499,018
2.39%
119,496
0.45%
07/31/2018
Vanguard Total Stock Market Index Fund
1,407,281
2.25%
39,040
0%
07/31/2018
iShares Russell 2000 ETF
1,139,396
1.82%
-609
0.02%
09/06/2018
Fidelity Select Biotechnology Portfolio
837,115
1.34%
0
0.07%
07/31/2018
Vanguard Extended Market Index Fund
580,219
0.93%
0
0.01%
07/31/2018
Tekla Healthcare Investors
515,115
0.82%
308,062
0.36%
12/31/2017
Driehaus Micro Cap Growth Fund
489,199
0.78%
18,431
0.76%
06/30/2018
iShares Russell 2000 Value ETF
473,661
0.76%
0
0.03%
09/06/2018
PRIMECAP Odyssey Aggressive Growth Fund
472,100
0.75%
0
0.03%
06/30/2018
373,044
0.6%
141,599
0.31%
05/31/2018
| Address |
1035 O'Brien Drive
Menlo Park California 94025
United States
|
|
Employees
|
- |
| Website |
http://www.adverum.com |
| Updated |
07/08/2019 |
| Adverum Biotechnologies, Inc. is a clinical-stage biotechnology company that engages in the development of novel gene therapies to treat patients with sight-threatening ophthalmic diseases. It focuses on treatment of wet age-related macular degeneration, alpha-1 antitrypsin deficiency, hereditary angioedema, friedreich's ataxia, severe allergy, color vision deficiency, and juvenile x-linked retinoschisis. The company was founded by Mark S. |
